{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"256"}]}],"title":"Month 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"250"}]}],"title":"Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"234"}]}],"title":"Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"216"}]}],"title":"Month 18"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"198"}]}],"title":"Month 24"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"177"}]}],"title":"Month 36"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"162"}]}],"title":"Month 48"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"140"}]}],"title":"Month 60"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"98"}]}],"title":"Month 72"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"21"}]}],"title":"Month 84"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"}]}],"title":"Month 96"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"}]}],"title":"Month 108"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"title":"Month 120"}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"299"}],"units":"Participants"}],"description":"Efficacy was assessed by the investigator at each scheduled visit using a binary (yes/no) response confirming the investigator's judgement of clinical benefit (via the question: \"Does investigator confirm that the subject continues to have clinical benefit from the study treatment\"). No other measures of efficacy were used in this study.","groups":[{"description":"0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines. Cabergoline may be combined in this arm for Cushing's Disease and Acromegaly patients.","id":"OG000","title":"Pasireotide Subcutaneous"},{"description":"10mg, 20mg, 40mg and 60mg. All doses to be taken q28days i.m. Strength is dependent on parent study guidelines","id":"OG001","title":"Pasireotide Long Acting Release (LAR)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Number of patients judged by the investigator to be clinically benefitting from treatment.","reportingStatus":"POSTED","timeFrame":"Baseline up to approximately 10 years","title":"Percentage of Patients With Clinical Benefit as Assessed by the Investigator","type":"SECONDARY","unitOfMeasure":"Participants"}